These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 15867235)

  • 1. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
    Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
    J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
    Arlen PM; Gulley JL; Todd N; Lieberman R; Steinberg SM; Morin S; Bastian A; Marte J; Tsang KY; Beetham P; Grosenbach DW; Schlom J; Dahut W
    J Urol; 2005 Aug; 174(2):539-46. PubMed ID: 16006888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
    Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
    BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
    Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
    Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
    Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
    Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
    Cavacini LA; Duval M; Eder JP; Posner MR
    Clin Cancer Res; 2002 Feb; 8(2):368-73. PubMed ID: 11839651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.